BI 1206

Drug Profile

BI 1206

Alternative Names: 6G 11; BI-1206

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioInvent International
  • Developer BioInvent International; University of Southampton
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD20 antigen modulators; Fc gamma receptor IIB antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 23 Oct 2017 BioInvent International plans a phase I/IIa trial for Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in first half of 2018
  • 01 Sep 2017 BioInvent has patents pending for BI 1206 in Japan
  • 01 Apr 2017 BioInvent has patents pending for BI 1206 in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top